Incyte 2013 Annual Report
to Stockholders
Jakafi® (ruxolitinib)
Prescribing Information

is a biopharmaceutical company focused on discovering, developing and commercializing proprietary small molecule drugs for oncology and inflammation.

Pivotal Phase III Data in Polycythemia Vera Show that Jakafi® (ruxolitinib) Achieved Superior Disease Control Compared to Best Available Therapies
Incyte Announces Preliminary Results of a Phase I/II Study of Combination Immunotherapy in Patients with Melanoma
Incyte Announces Full Results from Proof-of-Concept Phase II RECAP Trial of Jakafi in Combination with Capecitabine in Patients with Metastatic Pancreatic Cancer
Jakafi® (ruxolitinib)
Connecting to Access, Reimbursement, Education and Support
To learn more, click here